Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients

1. Treat Infection of Multiple Gene Mutation HIV Virus Strains.
2. Activate Human Antigen Presentation Reaction to HIV Specific Antigen.
3. The human antigen presenting cells (APCs) can take up and process HIV target antigen protein into small peptide fragments, and then HIV virus can be killed by APCs directly.

• Conducting an initial small, controlled trial to assess therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients without AIDS
• 20 HIV (+) patients with AIDS
• Positive HIV testing by standard RT-PCR assay or equivalent testing
• No symptoms of AIDS
• No clinical signs indicative of Severe or Critical Illness Severity
• HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix
• By the percutaneous route with the multiple puncture device
• Negative HIV testing by standard RT-PCR assay or equivalent testing after percutaneous use 3 weeks.
• Positive IGRA blood test with GP160 antigen after percutaneous use 21 days.
• Our trial duration will be up to 4 weeks.

• Conducting an initial small, controlled trial to assess therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients.
• 20 HIV (+) patients

Inclusion Criteria:

• HIV Positive
• Positive testing by standard RT-PCR assay or equivalent testing
• No AIDS Symptoms
• No clinical signs indicative of Severe or Critical Illness Severity
• Sign Informed Consent Form

Exclusion Criteria:

• Severe or Critical Illness Severity
• Pregnancy
• Breast-feeding
• The patients with other serious inter-current illness
• Serious Allergy
• Serious Bleed or Clot Tendency
• Serious side-effects of the biological product
• The prohibition of the biological product

Open Label